C - Chemistry – Metallurgy – 12 – Q
Patent
C - Chemistry, Metallurgy
12
Q
C12Q 1/68 (2006.01) C12Q 1/37 (2006.01) G01N 33/50 (2006.01)
Patent
CA 2508779
The present invention provides a method, an assay and a kit for providing an indication of abnormal cell function. It was surprisingly found that the change in the serum ADAM12 concentration in individuals was useful as a prognostic tool to predict the clinical outcome, complications and mortality following an abnormal cell function. The present inventors describes ADAM12 as a overall general marker for abnormal cell function, and the present inventor for the first time demonstrate that ADAM12 is an important indicator of fetal chromosomal disease and placenta function. Specifically ADAM12 is a good marker for e.g. Downs's syndrome, trisomy 18, preeclampsia, Turner syndrome in both first and second trimester. The present inventors developed an enzyme-linked immunosorbent assay (ELISA) and a time-resolved immunofluorometric assay for the quantification of ADAM12 in serum. The present application demonstrates in several examples the variation of the ADAM12 level in fetal abnormality and/or adverse pregnancy outcomes correlated gestational age when compared to normal controls. It is an object of the invention to provide an improvement of the existing marker tests that exhibits a decreased false positive rate.
Christiansen Michael
Froehlich Camilla
Laigaard Jennie
Norgaard-Pedersen Bent
Spencer Kevin
Gowling Lafleur Henderson Llp
Harold Wood Hospital
Kobenhavns Universitet
Statens Serum Institut
LandOfFree
Adam12, a novel marker for abnormal cell function does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Adam12, a novel marker for abnormal cell function, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Adam12, a novel marker for abnormal cell function will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1791481